vs

Side-by-side financial comparison of CervoMed Inc. (CRVO) and T Stamp Inc (IDAI). Click either name above to swap in a different company.

CervoMed Inc. is the larger business by last-quarter revenue ($1.8M vs $908.9K, roughly 1.9× T Stamp Inc). T Stamp Inc runs the higher net margin — -279.9% vs -356.1%, a 76.2% gap on every dollar of revenue. On growth, T Stamp Inc posted the faster year-over-year revenue change (-39.3% vs -46.6%). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs 7.3%).

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative conditions such as Alzheimer’s disease and other forms of dementia. It operates in the global biopharmaceutical market, with core R&D segments dedicated to addressing unmet medical needs for patients with progressive brain disorders.

T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.

CRVO vs IDAI — Head-to-Head

Bigger by revenue
CRVO
CRVO
1.9× larger
CRVO
$1.8M
$908.9K
IDAI
Growing faster (revenue YoY)
IDAI
IDAI
+7.3% gap
IDAI
-39.3%
-46.6%
CRVO
Higher net margin
IDAI
IDAI
76.2% more per $
IDAI
-279.9%
-356.1%
CRVO
Faster 2-yr revenue CAGR
IDAI
IDAI
Annualised
IDAI
25.9%
7.3%
CRVO

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CRVO
CRVO
IDAI
IDAI
Revenue
$1.8M
$908.9K
Net Profit
$-6.3M
$-2.5M
Gross Margin
Operating Margin
-376.4%
-224.9%
Net Margin
-356.1%
-279.9%
Revenue YoY
-46.6%
-39.3%
Net Profit YoY
-170.1%
57.7%
EPS (diluted)
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRVO
CRVO
IDAI
IDAI
Q4 25
$908.9K
Q3 25
$872.5K
Q2 25
$1.8M
$812.7K
Q1 25
$1.9M
$545.5K
Q4 24
$2.2M
$1.5M
Q3 24
$1.9M
$511.1K
Q2 24
$3.3M
$500.4K
Q1 24
$2.3M
$573.7K
Net Profit
CRVO
CRVO
IDAI
IDAI
Q4 25
$-2.5M
Q3 25
$-1.9M
Q2 25
$-6.3M
$-1.7M
Q1 25
$-4.9M
$-2.2M
Q4 24
$-6.7M
$-6.0M
Q3 24
$-4.8M
$-1.3M
Q2 24
$-2.3M
$-2.6M
Q1 24
$-2.5M
$-2.7M
Operating Margin
CRVO
CRVO
IDAI
IDAI
Q4 25
-224.9%
Q3 25
-203.0%
Q2 25
-376.4%
-207.0%
Q1 25
-276.6%
-396.5%
Q4 24
-334.9%
-81.2%
Q3 24
-278.2%
-523.7%
Q2 24
-91.1%
-524.7%
Q1 24
-110.6%
-496.7%
Net Margin
CRVO
CRVO
IDAI
IDAI
Q4 25
-279.9%
Q3 25
-219.1%
Q2 25
-356.1%
-210.7%
Q1 25
-255.2%
-395.5%
Q4 24
-310.2%
-401.5%
Q3 24
-245.1%
-245.7%
Q2 24
-70.4%
-519.3%
Q1 24
-107.1%
-466.9%
EPS (diluted)
CRVO
CRVO
IDAI
IDAI
Q4 25
$-0.37
Q3 25
$-0.72
Q2 25
$-0.69
Q1 25
$-0.89
Q4 24
$-3.14
Q3 24
$-0.55
$-1.06
Q2 24
$-3.19
Q1 24
$-3.97

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRVO
CRVO
IDAI
IDAI
Cash + ST InvestmentsLiquidity on hand
$33.5M
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$33.4M
$8.7M
Total Assets
$38.1M
$11.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRVO
CRVO
IDAI
IDAI
Q4 25
$6.0M
Q3 25
$5.4M
Q2 25
$33.5M
$292.1K
Q1 25
$35.2M
$1.1M
Q4 24
$38.9M
$2.8M
Q3 24
$46.7M
$598.0K
Q2 24
$45.1M
$659.5K
Q1 24
$6.4M
$816.7K
Stockholders' Equity
CRVO
CRVO
IDAI
IDAI
Q4 25
$8.7M
Q3 25
$6.1M
Q2 25
$33.4M
$2.4M
Q1 25
$34.6M
$4.1M
Q4 24
$39.2M
$3.0M
Q3 24
$45.6M
$5.4M
Q2 24
$50.0M
$750.4K
Q1 24
$5.3M
$1.4M
Total Assets
CRVO
CRVO
IDAI
IDAI
Q4 25
$11.2M
Q3 25
$11.2M
Q2 25
$38.1M
$5.7M
Q1 25
$38.6M
$6.6M
Q4 24
$43.1M
$8.6M
Q3 24
$48.9M
$10.6M
Q2 24
$53.2M
$5.2M
Q1 24
$8.0M
$5.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRVO
CRVO
IDAI
IDAI
Operating Cash FlowLast quarter
$-6.5M
$2.0M
Free Cash FlowOCF − Capex
$2.0M
FCF MarginFCF / Revenue
215.4%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-5.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRVO
CRVO
IDAI
IDAI
Q4 25
$2.0M
Q3 25
$-4.0M
Q2 25
$-6.5M
$-2.1M
Q1 25
$-3.9M
$-1.5M
Q4 24
$-8.1M
$-2.7M
Q3 24
$-4.9M
$-2.4M
Q2 24
$-2.2M
$-1.6M
Q1 24
$-1.4M
$-2.2M
Free Cash Flow
CRVO
CRVO
IDAI
IDAI
Q4 25
$2.0M
Q3 25
$-4.0M
Q2 25
$-2.1M
Q1 25
$-1.6M
Q4 24
$-2.7M
Q3 24
$-2.4M
Q2 24
$-1.6M
Q1 24
$-2.2M
FCF Margin
CRVO
CRVO
IDAI
IDAI
Q4 25
215.4%
Q3 25
-459.6%
Q2 25
-258.6%
Q1 25
-289.2%
Q4 24
-182.9%
Q3 24
-475.4%
Q2 24
-320.9%
Q1 24
-376.6%
Capex Intensity
CRVO
CRVO
IDAI
IDAI
Q4 25
0.8%
Q3 25
0.0%
Q2 25
0.2%
Q1 25
6.8%
Q4 24
0.1%
Q3 24
0.7%
Q2 24
1.3%
Q1 24
0.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons